# Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)

> **NCT05757544** · PHASE2 · WITHDRAWN · sponsor: **Marinus Pharmaceuticals**

## Conditions studied

- Status Epilepticus

## Interventions

- **DRUG:** IV Ganaxolone
- **DRUG:** IV Placebo

## Key facts

- **NCT ID:** NCT05757544
- **Lead sponsor:** Marinus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-04-01
- **Primary completion:** 2026-02
- **Final completion:** 2026-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** for business reasons
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05757544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05757544, "Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05757544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*